Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
175. (EP2443106) HETEROCYCLYLAMINOPYRIMIDINES AS KINASE INHIBITORS

Application Number: 10725721 Application Date: 17.06.2010
Publication Number: 2443106 Publication Date: 25.04.2012
Publication Kind : A1
Prior PCT appl.: Application Number:EP2010058574 ; Publication Number: Click to see the data
IPC:
C07D 403/12
A61K 31/506
A61P 29/00
A61P 37/00
C07D 413/12
[IPC code unknown for C07D 403/12][IPC code unknown for A61K 31/506][IPC code unknown for A61P 29][IPC code unknown for A61P 37][IPC code unknown for C07D 413/12]
Applicants: CELLZOME LTD
Inventors: SUNOSE MIHIRO
MAJOR JEREMY
HARRISON RICHARD JOHN
FREEMAN JAY
MOREL ADELINE
Priority Data: 09163098 18.06.2009 EP
10725721 17.06.2010 EP
10725721 17.06.2010 EP
Title: (FR) HÉTÉROCYCLYLAMINOPYRIMIDINES SERVANT D'INHIBITEURS DE KINASES
(EN) HETEROCYCLYLAMINOPYRIMIDINES AS KINASE INHIBITORS
(DE) HETEROCYCLYLAMINOPYRIMIDINE ALS KINASEHEMMER
Abstract:
(FR) La présente invention concerne des composés de formule (I), dans laquelle les R1 à R6 et T0 ont les significations telles que citées dans la description et les revendications. Lesdits composés sont utiles comme inhibiteurs de la ZAP-70, de la Syk ou de la JAK3 dans le traitement ou la prophylaxie de troubles immunologiques, inflammatoires, auto-immuns, allergiques, et de maladies à médiation immunologique. L'invention concerne également des compositions pharmaceutiques comprenant lesdits composés, la préparation de tels composés ainsi leur utilisation comme médicaments.
(EN) The invention relates to compounds of formula (I), wherein R1 to R6 and T0 have the meaning as cited in the description and the claims. Said compounds are useful as inhibitors of ZAP-70, Syk or JAK3 for the treatment or prophylaxis of immunological, inflammatory, autoimmune, allergic disorders, immunologically-mediated diseases. The invention also relates to pharmaceutical compositions including said compounds, the preparation of such compounds as well as the use as medicaments.